Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03104699 · ClinicalTrials.gov registry record · Phase 1

A Study of AGEN2034 in Advanced Tumors and Cervical Cancer

A Phase 1 study of Cervical Cancer and Advanced Cancer, sponsored by Agenus.

Completed
Registry status
Phase 1
Development phase
211
Enrollment target
20
Study locations

NCT03104699 is a Phase 1 study of Cervical Cancer and Advanced Cancer that has completed, run by Agenus. The registered enrollment target is 211 participants, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (63% lower). The trial reports 20 study locations across 17 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03104699, a Phase 1 study of Cervical Cancer and Advanced Cancer, has completed, sponsored by Agenus.

COMPLETED
Registry status
Phase 1
Development phase
211 participants
Enrollment target
20
Study locations

Study Summary

This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed after a platinum-based treatment regimen.

Conditions Studied

Cervical Cancer Advanced Cancer

Interventions

  • DRUG AGEN2034

Study Locations (20)

California

  • City of Hope - Duarte
  • University of Southern California - Keck School of Medicine - Los Angeles

Florida

  • Sylvester Comprehensive Cancer Center - Miami
  • Florida Cancer Specialists & Research Institute - Sarasota

Rio Grande do Sul

  • Hospital de Caridade de Ijuí - Ijuí
  • Hospital Mãe de Deus - Porto Alegre

Arizona

  • HonorHealth Research Institute - Scottsdale

Georgia

  • Augusta Oncology - Augusta

Illinois

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University - Chicago

Massachusetts

  • Dana Farber Cancer Institute - Boston

Ohio

  • The Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 211 participants
Start Date 2017-04-11
Est. Completion 2022-06-15
Phase Phase 1

Sponsor

Agenus

24 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03104699

The ClinicalTrials.gov registry entry for NCT03104699 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (63% lower). The listed sponsor is Agenus, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which AGEN2034 is the first listed.

NCT03104699 reports 20 study locations spanning 17 distinct geographic areas - top geographies include California, Florida, Rio Grande do Sul.

Frequently Asked Questions

What is clinical trial NCT03104699 about?

NCT03104699 is a clinical study titled "A Study of AGEN2034 in Advanced Tumors and Cervical Cancer". This is a 2-part trial: a Phase 1, open-label, dose-escalation study in participants with metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate efficacy in participants with recurrent, unresectable, or metastatic (advanced) cervical cancer that has progressed ...

What is the current status of trial NCT03104699?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 211 participants. The study started on 2017-04-11. Estimated completion is 2022-06-15.

What conditions does trial NCT03104699 study?

This clinical trial studies the following conditions: Cervical Cancer, Advanced Cancer.

What interventions are being tested in trial NCT03104699?

The interventions under investigation include: AGEN2034 (DRUG).

Who is sponsoring clinical trial NCT03104699?

This trial is sponsored by Agenus, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03104699 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cervical Cancer

All registered trials for this condition

Advanced Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.